Stemson is going to use minipigs in the next stage of their hair cloning research
- Thread starter werefckd
- Start date
Or maybe nobody wants to waste their time to constantly provide links and evidence to some annoying f*cks who can get the information they so desire by just going through the past pages on the thread. No one owes you their time and undivided attention, go find it for yourself.
I don't have a link. I don't work for HMI, I have no reason to save links, and I don't feel like searching for it for you. 2 people have emailed her, including a chinese hair loss blogger and her response was the same to both of them
I don't know. Last info we got was that the hair loss trial would be in Australia
- Reaction score
- 1,335
They don't disappear, they are just ignoring you. That's a huge difference.
Not true because they always show up again with some defensive comment/bs excuse for not backing up their claims when called up.
I just asked for a link of the claim, nothing special. It’s ridiculous that some people get offended about that.
I told you I don't have a link. What do you want me to do, google and dig through the threads to find it for you?
Feel free to email Rui-ping yourself
I don’t want you to do anything, just wanted to understand if we knew for a fact that Hope Med had applied for clinical trials for hairloss treatment or if it is conjecture. And seems like it is a conjecture so I already got the answer.
I would think Rui-ping would know, but ok
I agree she knows, too bad nobody showed a statement from her regarding that, so it’s just a conjecture.
They did. They showed an email from her
Literally right below that paragraph, they say that their first indication for the primary drug is Androgenetic Alopecia (female and male) and endo. You do this all the time on here, you cherry pick information and in this case it's literally one paragraph later. No one is saying that the company was formed to be a hair loss company, they're trying to be a major biotech company that specializes in treatment pathways involving prolactin, which touches on some major womens health issues such as cancer. This doesn't change that hair loss is listed as one of two primary indications. I see why you would think this is comparable to Samumed, but the difference is that this company was formed and subsequently funded based on the licensing agreement with Bayer after preclinical work for hairloss was already completed. Samumed said they had the cure to all diseases and raised a lot of money from unqualified investors, not top tier biotech venture funds.Lol and do you think Hopemed got $56 million dollar for their AA prolactin treatment? There isn't a lot of difference with samumed.
The focus of Hopemed isn't balding.
From press release:
HopeMed focuses on the three major disease areas of women's health, endocrine, and cardiovascular diseases
Hope Medicine completed US$56 million in Series B financing, strengthening capabilities of global innovation
SHANGHAI, May 6, 2021 /PRNewswire/ -- Recently, the global innovative drug R&D company Hope Medicine Inc. (referred to as "HopeMed") announced the completion of a Series B...www.asiaone.com
Previously, HopeMed has signed a world-wide exclusive license agreement with Bayer AG on the development and commercialization of a human antibody (HMI-115) targeting the prolactin (PRL) receptor for the treatment of male and female pattern hair loss, endometriosis and other chronic diseases with dysregulated PRL signaling. Under the terms of the license agreement, Hope Medicine will develop and globally commercialize the novel PRL receptor antibody based on intellectual property from Bayer. At present, HMI-115 has completed phase I clinical trials in the European Union, with positive safety results. The global multi-center phase II clinical trials for androgenic alopecia and endometriosis will soon be launched.
Last edited:
They didn't get the funding "just" for the hairloss treatment, they got funding because the people who invested in them think they can be a massive biotech company and hairloss just so happens to be one of the first of many indications they will pursue. Unless you're dealing with incredibly niche fields (like Stemson is with cloning), most biotech startups are going to hope to offer their therapies for a wide range of indications.
Hairloss is also easily the least profitable indication that they will pursue even if they outright cure it with HMI115, and for that reason they probably would not have gotten this funding without other indications. This is why many larger biotech companies like Bayer would rather license something like this out then develop it in house.
Last edited:
To an extent. If not for hair loss they wouldn't have another pipeline. There's little evidence that it will work for endometriosis, so that's a gamble. The NHP model shows that it works for hair loss, so that's the nearly sure bet. That also makes bph and pc a strong possibility when combined with the research on that, and the link between bph and hair loss. Likely the thought process of the investors was, "worst case scenario we have a working hair loss drug, and we will get our investment back with a profit. If the drug works in other conditions, and the rest of their pipeline proves out then we have a gold mine." That would be my reasoning behind investing at least. Without the observational evidence behind hair loss the investment becomes a lot more speculative.
Last edited:
So, that Joe Tillman hairloss industry influencer guy had access to all the presentations of GHLS2021(edit: I think he even worked for the summit editing the videos and stuff), including the Stemson one, according to the description of a video he posted:
Someone could get in touch with him and ask if he can tell us the main points that was shared during the Stemson presentation .